Department of Thoracic Surgery, Qi Lu Hospital, Shandong University, Jinan, Shandong Province, China.
Ann Surg Oncol. 2011 Jul;18(7):2048-56. doi: 10.1245/s10434-010-1510-5. Epub 2011 Feb 3.
The aims of this work are to detect the expression levels of metastasis-associated protein 1 (MTA1) in patients with early-stage non-small cell lung cancer (NSCLC), and to investigate the relationship of MTA1 protein with clinicopathologic factors, tumor angiogenesis, and prognosis.
One hundred and two patients with pathologic stage I NSCLC who successfully underwent curative surgical resection were enrolled in this study. Immunohistochemical staining for MTA1 and CD34 was performed using the streptavidin-peroxidase method, and intratumoral microvessel density (MVD) was recorded by counting CD34-positive immunostained endothelial cells. All statistical analyses were performed with SPSS statistical software to determine the effects of MTA1 protein on clinicopathologic factors, tumor angiogenesis, and prognosis.
MTA1 protein overexpression was detected in 41 cases and was significantly associated with MVD (P = 0.008). MTA1 protein overexpression and high MVD were significantly associated with tumor relapse (P = 0.004 and 0.007) and poor 5-year disease-free survival (P = 0.001 and 0.004). Patients with MTA1 protein overexpression and high MVD had significantly poor overall survival (P = 0.005 and 0.043) and disease-specific survival (P = 0.006 and 0.031) at 5 years after operation. Multivariate analysis demonstrated that MTA1 protein overexpression was an independent prognosticator for unfavorable disease-free, overall, and disease-specific survival (P = 0.011, 0.024, and 0.046).
MTA1 protein overexpression is common in early-stage NSCLC and is significantly associated with tumor angiogenesis and poor survival. These findings suggest that MTA1 may have clinical potential as a promising predictor to identify individuals with poor prognostic potential and as a possible novel target molecule of antiangiogenic therapy for patients with early-stage NSCLC.
本研究旨在检测早期非小细胞肺癌（NSCLC）患者中转移相关蛋白 1（MTA1）的表达水平，并探讨 MTA1 蛋白与临床病理因素、肿瘤血管生成及预后的关系。
本研究共纳入 102 例经病理分期为 I 期 NSCLC 且成功接受根治性手术切除的患者。采用链霉亲和素-过氧化物酶法检测 MTA1 和 CD34 的免疫组织化学染色，计数 CD34 阳性免疫染色的内皮细胞以记录肿瘤内微血管密度（MVD）。所有统计分析均采用 SPSS 统计软件进行，以确定 MTA1 蛋白对临床病理因素、肿瘤血管生成及预后的影响。
41 例患者中检测到 MTA1 蛋白过表达，且与 MVD 显著相关（P = 0.008）。MTA1 蛋白过表达和高 MVD 与肿瘤复发（P = 0.004 和 0.007）及 5 年无病生存率不良（P = 0.001 和 0.004）显著相关。MTA1 蛋白过表达和高 MVD 的患者总生存（P = 0.005 和 0.043）和疾病特异性生存（P = 0.006 和 0.031）显著不良。多因素分析表明，MTA1 蛋白过表达是无病生存、总生存和疾病特异性生存不良的独立预后因素（P = 0.011、0.024 和 0.046）。
MTA1 蛋白过表达在早期 NSCLC 中较为常见，与肿瘤血管生成和不良生存显著相关。这些发现表明，MTA1 可能具有临床潜力，可作为一种有前途的预测因子，用于识别预后不良的个体，并可能成为早期 NSCLC 抗血管生成治疗的新靶点分子。
